Pharmaceutical Tariffs 2026: 100% Section 232 Duties Effective July 31 — Rates, Exemptions & Importer Checklist
Now finalized as a Section 232 proclamation: a 100% tariff on patented pharmaceuticals, their APIs, and key starting materials takes effect July 31, 2026 for Annex III companies and September 29, 2026 for all others. Generics, biosimilars, US-origin products, and specialty drugs are exempt.
Update — Section 232 Pharmaceutical Tariffs: The July 31, 2026 Change
<!-- pharma-jul2026 -->Bottom line (June 2026): The April announcement is no longer just a "framework." It is now a finalized Section 232 presidential proclamation, and the headline 100% tariff on patented pharmaceuticals is locked in. It takes effect July 31, 2026 for the 17 large pharmaceutical companies named in Annex III of the proclamation, and September 29, 2026 for all other importers. The duty applies to brand/patented drugs listed in the FDA's Orange Book or Purple Book, plus their active pharmaceutical ingredients (APIs) and key starting materials. Generics, biosimilars, U.S.-origin products, and a defined list of specialty therapies are exempt.
If your imports are branded, on-patent finished drugs or the APIs that go into them, treat July 31, 2026 as your real planning deadline — it is roughly seven weeks out — and confirm now whether your supplier appears on the Annex III list.
What's actually new vs. the April announcement
The original April 2, 2026 news was a White House announcement of intent. It has since been issued as a formal Section 232 of the Trade Expansion Act of 1962 proclamation (the national-security tariff authority, following a Commerce Department investigation). The finalized text added the specifics that matter for filing:
- Scope is patent-based, not category-based. A drug is covered only if it is (a) subject to a valid, unexpired U.S. patent and (b) listed in the FDA's Orange Book (small-molecule) or Purple Book (biologics). APIs and key starting materials for those covered articles are swept in.
- Two effective dates, not one. The 17 large manufacturers in Annex III face the duty first, on July 31, 2026. All other importers get until September 29, 2026.
- A formal exemption/annex structure (Annex II MFN-pricing companies, Annex IV exempt tariff codes, specialty-product carve-outs) now governs who pays the full 100% versus a reduced or zero rate.
Who pays what — effective date and exemptions by category
| Category | Tariff treatment | When |
|---|---|---|
| Patented drug (Orange/Purple Book) imported by an Annex III company | 100% | July 31, 2026 |
| Patented drug (Orange/Purple Book) imported by any other company | 100% | September 29, 2026 |
| Company with an approved U.S. onshoring plan | Reduced to 20% (through ~April 2030) | Same dates |
| EU, Japan, South Korea, Switzerland, Liechtenstein origin | Reduced to 15% | Same dates |
| United Kingdom origin | 10% | Same dates |
| Generic pharmaceuticals & biosimilars | Exempt (0%) | n/a |
| U.S.-origin finished products and APIs | Exempt (0%) | n/a |
| Companies with pre-April-2 MFN pricing agreements (Annex II, ~13 firms) | Exempt through Jan 20, 2029 | n/a |
| Specialty products — orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell & gene therapies, antibody-drug conjugates, CBRN countermeasures, animal-health | Exempt (0%) | n/a |
| Products in Annex IV exempt 10-digit HTS codes; R&D prototypes (HTSUS 9817.85.01) | Exempt (0%) | n/a |
Reduced country rates and onshoring relief reflect the proclamation's negotiated-partner and onshoring provisions; confirm the current annex text for your specific product and supplier before relying on a reduced or zero rate.
What importers should do now
- Check the patent/listing status of every SKU. The duty hinges on Orange Book / Purple Book listing plus a live U.S. patent. Off-patent and generic products fall outside scope entirely — confirm this in writing per product.
- Identify your supplier's annex position. If your manufacturer is in Annex III, your real deadline is July 31, 2026, not September. Ask suppliers to confirm Annex III, Annex II (MFN), or onshoring-plan status.
- Map API and key-starting-material exposure separately. Even if a finished drug is exempt, its APIs may be covered (and vice versa). Classify both legs of the supply chain.
- Re-run landed-cost models at 100%, 20%, 15%, and 0%. The spread is enormous; the rate you actually pay depends on origin country, onshoring status, and exemption category — not a single headline number.
- Resize your customs bond if needed. A jump to 100% duty on high-value pharma entries can blow past your continuous-bond limit and trigger a CBP bond-insufficiency notice.
💡 Note: Sources differ slightly on the proclamation's exact issuance date (early April 2026 — April 2 vs. April 6 are both reported). The effective dates (July 31 and September 29, 2026) and the 100% rate are consistent across the legal advisories tracking this action.
Pharmaceutical Tariffs April 2026: Up to 100% Duties, Exemptions, and What Importers Should Check Now
The pharmaceutical tariff story moved from rumor to operating reality on April 2, 2026.
The White House issued a fact sheet describing a new tariff framework for certain patented pharmaceutical products and ingredients.
What changed on April 2, 2026
The new regime can impose tariffs of up to 100% on certain patented pharmaceutical products and ingredients. The exact outcome depends on company status, product type, origin, and whether the manufacturer enters specific pricing or onshoring arrangements.
The framework importers need to know
| Bucket | Working outcome to evaluate |
|---|---|
| Covered patented/branded pharmaceutical imports with no qualifying deal | Up to 100% tariff exposure |
| Companies entering onshoring arrangements | Lower-rate path, reported at 20% instead of 100% |
| Certain countries with negotiated treatment | Lower tariff treatment, commonly cited around 15% for listed countries |
| MFN-deal participants and certain exempt categories | Potential 0% outcome for the defined period or product class |
The dates that matter
The framework uses delayed enforcement windows:
- Larger pharmaceutical companies: 120-day window → July 31, 2026
- Smaller pharmaceutical companies: 180-day window → September 29, 2026
What products are most likely to drive questions
Current discussion is centered on:
- patented branded drugs
- certain imported active pharmaceutical ingredients (APIs)
- products tied to high U.S. pricing or domestic-manufacturing leverage
The first screening question is not "Do we import pharmaceuticals?" It is: Do we import products that fall into the patented/branded/strategic bucket described in the White House action?
Exemptions and lower-rate paths
Reported exempt or favored categories include:
- orphan drugs
- animal-health drugs
- certain specialty pharmaceutical products
- products covered by specific pricing or MFN-style arrangements
Reported lower-rate paths include:
- 15% for imports from certain previously negotiated partners (EU, Japan, Korea, Switzerland, Liechtenstein)
- 20% for companies entering qualifying U.S. onshoring arrangements
What importers should check now
- Build a covered-product list of patented, branded, or strategic imports
- Identify whether APIs are part of the exposure
- Map company-size timing (120 vs 180 days)
- Review whether any lower-rate path could apply
- Model customer pricing impact early
Bottom line
The pharmaceutical tariff regime announced on April 2, 2026 is a targeted policy designed to force pricing and manufacturing decisions in a strategically sensitive sector. The important takeaway is not simply "100% tariffs are coming." It is that the policy has timing windows, exemptions, lower-rate paths, and product-level differences that make early screening essential.
If your business imports branded drugs, patented products, or APIs, the work should start now, not in late July.